Skip to main content

Day: March 8, 2023

Shoals Technologies Group, Inc. Announces Pricing of Secondary Offering of 24,501,650 Shares of Class A Common Stock by Selling Stockholders

PORTLAND, Tenn., March 07, 2023 (GLOBE NEWSWIRE) — Shoals Technologies Group, Inc. (Nasdaq: SHLS) (the “Company”) today announced the pricing of the previously announced underwritten public offering of an aggregate of 24,501,650 shares of the Company’s Class A common stock by certain selling stockholders affiliated with Dean Solon (collectively, the “Selling Stockholders”), at a price to the public of $24.70 per share. The Company will not receive any of the proceeds from the sale of Class A common stock offered by the Selling Stockholders. The Selling Stockholders also granted the underwriter a 30-day option to purchase up to an additional 3,675,247 shares of Class A common stock. The Company’s Class A common stock is listed on the Nasdaq Global Market under the symbol “SHLS.” The offering is expected to close on March 10, 2023,...

Continue reading

Magna Announces CAD Senior Notes Offering

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES AURORA, Ontario, March 07, 2023 (GLOBE NEWSWIRE) — Magna International Inc. (TSX: MG; NYSE: MGA) today announced that it has entered into an agency agreement providing for the issuance, by way of private placement in each of the provinces of Canada, of CAD$350 million aggregate principal amount of senior unsecured notes due 2031. The notes will bear interest at an annual rate of 4.95% and will mature on January 31, 2031. The offering is expected to close on March 10, 2023, subject to customary closing conditions. Magna intends to use the net proceeds from this offering to finance a portion of the cost of its proposed acquisition of the Veoneer Active Safety business (the “Veoneer Acquisition”) and to pay related fees and expenses, and for general...

Continue reading

Miromatrix Medical Inc. Announces Pricing of $10 Million Public Offering of Common Stock

EDEN PRAIRIE, Minn., March 07, 2023 (GLOBE NEWSWIRE) — Miromatrix Medical Inc. (“Miromatrix”) (Nasdaq: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients’ lives, today announced the pricing of an underwritten public offering of 6,250,000 shares of its common stock at a price to the public of $1.60 per share, before underwriting discounts and commissions. The gross proceeds to Miromatrix from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Miromatrix are expected to be $10.0 million. The offering is expected to close on March 10, 2023, subject to customary closing conditions. Additionally, Miromatrix has granted the underwriters a 30-day option to purchase up to an additional 937,500...

Continue reading

Digital Therapeutics Market is Projected to Surpass USD 20.5 Billion by 2030 at a CAGR of 25.9% from 2022 to 2030; Increased Cost-Effectiveness and Reliability of Digital Health Technology to Foster Market Growth

SkyQuest, a reputed research firm, has released a comprehensive report on the digital therapeutics market that provides crucial insights into the major trends and significant developments in the industry worldwide. This report is a must-read for decision-makers who want to make informed strategic decisions, as it features case studies of well-known companies operating in the market. Furthermore, it evaluates the competitive landscape, growth opportunities, and effective strategies for achieving growth. This information is crucial for businesses looking to expand their presence in the market. Westford, USA, March 07, 2023 (GLOBE NEWSWIRE) — Asia Pacific emerged as the key growth contributor to the digital therapeutics market due to the increasing demand for treating chronic medical conditions in the Asia Pacific region. Conditions...

Continue reading

FDA Accepts Mesoblast’s Resubmission of the Biologic License Application for Remestemcel-L In Children with Steroid-Refractory Acute Graft Versus Host Disease as a Complete Response and Sets Goal Date of August 2, 2023

If Approved, Remestemcel-L will be the First Allogeneic “Off-the-Shelf” Cellular Medicine in the US, and the First Therapy for Children Under 12 Years Old with SR-aGVHD. NEW YORK, March 07, 2023 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the United States Food and Drug Administration’s (FDA) Office of Therapeutic Products (OTP) has accepted the Company’s Biologics License Application (BLA) resubmission for remestemcel-L in the treatment of children with steroid-refractory acute graft versus host disease (SR-aGVHD). FDA considers the resubmission to be a complete response and has set a Prescription Drug User Fee Act (PDUFA) goal date of August 2, 2023. “Over the last two years we have worked tirelessly to address the...

Continue reading

LGI Homes Opens New Community near Tucson

Red Rock Village features a stunning lineup of single-family homes priced from the low-$300sThe Snowflake plan by LGI Homes LGI Homes at Red Rock Village offers new, move-in ready homes and world-class amenities in Red Rock, Arizona. Pricing starts from the $300s.TUCSON, Ariz., March 07, 2023 (GLOBE NEWSWIRE) — LGI Homes, Inc. (NASDAQ: LGIH) today announced the grand opening of Red Rock Village, its newest community in the Tucson market. Located in Red Rock, Arizona, just 15 minutes north of Marana, this incredible community offers new-construction, single-family homes in a vibrant, amenity-filled community. LGI Homes offers a variety of open-concept floor plan options at Red Rock Village, with new homes ranging from efficient 3-bedroom plans with large living areas, to grand 5-bedroom homes with designer kitchens and upstairs...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.